BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-188@pharmaconomics
DTSTAMP:20260707T034519Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:CGEM Phase 3 — Zipalertinib (estimated date)
DESCRIPTION:Phase 3 trial results for Zipalertinib in EGFR ex20ins NSCLC are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/188
URL:https://www.pharmaconomics.com/e/188
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CGEM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR